Board of Directors:
Dr Paul Rodgers - Executive Chairman
An entrepreneur with thirty years' experience in the life sciences industry, who has co-founded ten biotechnology companies. Paul has led a number of companies from start up to technology commercialisation and achieved significant exits for early stage investors. He has experience in the healthcare, agriculture and food sectors of biotechnology with particular experience in biomarkers.
A seasoned Board Director, Paul has extensive experience in technology commercialisation, raising investment finance, the management of R&D, strategic business development, and licensing and protection of intellectual property.
Mr Mahesh Shah - Non-Executive Director
Mr Shah was a founding director of Nucare plc, a company operating in the Pharmaceutical Sector. He became the Sales & Marketing Director in 2000 and was CEO from 2002-2009, growing the company organically as well as by joint ventures and acquisitions with operations in the UK as well as overseas.
He managed 250 employees and a wide shareholder base with over 700 shareholders. In November 2007 he led a successful trade sale for the company realising an enterprise value of approximately £70 million.
Dr Adrian Woolfson - Non-Executive Director
Dr Wolfson studied medicine at Balliol College, Oxford UK and Gonville & Caius College, Cambridge UK, and worked as a doctoral student, Charles and Katharine Darwin Research Fellow, Wellcome Trust Research Fellow and National Federation of Cancer USA Fellow with Dr César Milstein at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge UK.
His research interests include alternative splicing, protein folding and proteomics. He was a founding member of ProteinLogic and co-inventor of the core patent.
Professor Herman Waldmann - Non-Executive Director
Professor of Pathology, University of Oxford, Head of the Sir William Dunn School of Pathology, University of Oxford UK, Head of the Therapeutic Immunology Group, University of Oxford UK and a Senior Fellow at Lincoln College, Oxford UK.
His research interests include basic research into the mechanisms of immune tolerance and how these can be harnessed, using monoclonal antibodies and other modern biotherapeutics. His aim is to develop clinical treatments for human diseases that involve disregulation or inappropriate reactions of the immune system such as in autoimmunity or transplant rejection.
Dr Alex Betz - Non-Executive Director
Dr Betz is currently a Group Leader at the MRC Laboratory of Molecular Biology, Cambridge UK.
Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. He has also worked in the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA. His research interests include the regulation of lymphocyte migration by chemokines.
Sir Gregory Winter - Specialist Advisor to the Board
Sir Gregory is the joint Head of the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology, Cambridge UK, Deputy Director of the MRC Centre for Protein Engineering, Cambridge UK and is a Fellow of Trinity College, Cambridge UK. He founded two Cambridge UK-based biotechnology companies, Cambridge Antibody Technology and Domantis.
His research interests include combinatorial proteins, vaccines and antibodies.